EligibleTrials

Comparison of Oral Administration of a JAK Inhibitor in Rheumatoid Arthritis

Recruiting · NCT07674134 · Observational (researchers observe without assigning treatment) · Lead sponsor: Centre Hospitalier Princesse Grace

View the official record on ClinicalTrials.gov →
Rheumatoid arthritis

What this trial is about

The aim of this study is to offer patients two treatment options: morning or evening administration of a JAK inhibitor prescribed within the framework of its marketing authorization, according to the EULAR response. The objective is to determine whether evening administration in our patients with rheumatoid arthritis provides greater efficacy than morning administration in our patients taking JAK inhibitors once daily.

Who can take part

Age range
18 Years and older
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)

Inclusion criteria

Exclusion criteria

Where it is running

1 location listed.

Read the full protocol, contacts and eligibility on ClinicalTrials.gov →

Get notified when new trials open

One email when new recruiting trials are added. Unsubscribe anytime.